Health Trials

Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosis Patients

ConditionOsteoporosis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age20-120
SponsorShinshu University

About this trial

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:

SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months

Eligibility criteria

Qualifiers

osteoporosis patients

Disqualifiers

not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant

Trial design

Treatments tested in this trial

  • SERM "Viviant®Tablet 20mg" and ELD "Edirol®Tablet 0.75ug"
  • Bisphosphonates and ELD "Edirol®Tablet 0.75ug"
  • ELD "Edirol®Tablet 0.75ug"

Treatment groups

90 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Shinshu University

Lead sponsor

Source ClinicalTrials.gov